Aurora Cannabis (NASDAQ:ACB) versus Adherex Technologies (NASDAQ:FENC) Head to Head Contrast

Aurora Cannabis (NASDAQ:ACB) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Profitability

This table compares Aurora Cannabis and Adherex Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-23.70%	3.72%	3.03%
Adherex Technologies	-6.09%	-5.71%	-2.37%

Analyst Recommendations

This is a summary of recent recommendations for Aurora Cannabis and Adherex Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	2	2	1	0	1.80
Adherex Technologies	1	1	4	0	2.50

Adherex Technologies has a consensus target price of $17.00, indicating a potential upside of 60.68%. Given Adherex Technologies’ stronger consensus rating and higher probable upside, analysts clearly believe Adherex Technologies is more favorable than Aurora Cannabis.

Volatility and Risk

Aurora Cannabis has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Adherex Technologies has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500.

Institutional & Insider Ownership

47.6% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are owned by institutional investors. 0.0% of Aurora Cannabis shares are owned by company insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Aurora Cannabis and Adherex Technologies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	$321.28 million	1.05	-$88.13 million	($0.98)	-5.21
Adherex Technologies	$59.22 million	6.29	-$9.74 million	($0.13)	-81.38

Adherex Technologies has lower revenue, but higher earnings than Aurora Cannabis. Adherex Technologies is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Summary

Adherex Technologies beats Aurora Cannabis on 10 of the 14 factors compared between the two stocks.

About Aurora Cannabis

Aurora Cannabis Inc. is a Canadian cannabis company headquartered in Edmonton, Alberta. Founded in 2013, the company develops, produces, distributes and sells cannabis and cannabis-derived products for medical and adult-use markets. Its shares trade on the Toronto Stock Exchange and the Nasdaq under the symbol ACB. Aurora’s product portfolio includes dried cannabis flower, pre-rolls, cannabis oils, softgels, vapes and other cannabis extracts. The company markets products through brands such as Aurora, San Rafael ’71, Daily Special and CanniMed, with offerings varying by market and applicable regulations.

About Adherex Technologies

Fennec Pharmaceuticals, Inc., formerly known as Adherex Technologies, is a biopharmaceutical company focused on developing and commercializing therapies for pediatric cancer. The company’s lead product is PEDMARK (sodium thiosulfate), a platinum-based chemotherapy protective agent intended to reduce the risk of cisplatin-induced ototoxicity, or hearing loss, in children with localized, non-metastatic solid tumors. PEDMARK received approval from the U.S. Food and Drug Administration in 2022. Fennec markets the product in the United States through its commercial operations and has pursued regulatory and commercialization opportunities in international markets.